performed on sections using the Dako 22c3 antibody to determine PD-L1 expression. Result: A total of 99 samples were tested for PD-L1. There was sufficient material for PD-L1 testing in 95% (n¼94). Male 62%, female 38%, age range 26-84. EBUS-TBNA accounted for 79% of samples, percutaneous Fine Needle Aspirate (FNA) 11%, pleural fluid samples 7%, bronchial brush 2% and endoscopic ultrasound FNA 1%. Table- 1 provides a breakdown of the methods of sample acquisition with adequacy rates and PD-L1 expression. Overall PD-L1 expression was highly (50%) positive in 34/94 (36%), low (1-50%) positive in 38/94 (40%), and negative in 22/94 (23%). The proportion of patients expressing high (50%) PD-L1 positivity in the different pathological subtypes were: adenocarcinoma 23/62 (37%), squamous cell carcinoma 8/21 (38%), NSCLC-NOS 3/9 (33%). The proportion of patients with low (1-50%) PD-L1 positivity were: adenocarcinoma 27/62 (44%), squamous cell carcinoma 9/21 (43%), NSCLC-NOS 2/9 (22%).
Background: Large cell neuroendocrine carcinomas of the lung (LCNECs) are rare neoplasms with few therapeutics options especially for stage IV diseases. Pathological diagnostic of LCNECs may be difficult with low interobserver reproducibility and need immunohistochemical (IHC) staining. Immune checkpoint inhibitors targeting tumoral and immune cells interaction have revolutionized the treatment of NSCLC, but few data's are available on LCNECs immune environment and particulary the expression of PD-L1 on both tumors (TC) and immune infiltrating (IC) cells. The objective of the present study is to determine the pattern of PD-L1 staining in a cohort of LCNECs patients. Method: Clinical files and tumors biopsies of patients (pts) with a LCNEC diagnosed between 01.01.2014 and 31.12.2016 were retrospectively collected (GFPC 03-2017). All histological samples were centrally reviewed by a panel of six independent pathologists, according to the WHO 2015 classification. LCNEC was confirmed and PD-L1 expression was determined both in TC and IC, using the anti-PD-L1 antibody 22C3 (kit and automat Dako). PD-L1 expression was scored on TC as the percentage of PD-L1 positive cells (0 to 100%). PD-L1 expression on IC was determined as follows: IC0: positive IC representing<1% of the tumor surface; IC1: positive IC representing>¼1% but<5% of the tumor surface; IC2: positive IC representing>¼5% but<10% of the tumor surface; and IC3: positive IC representing>10% of the tumor surface. Result: Eighty-six pts were initially included in the study. Twenty-eight (32%) of them were excluded for non-LCNEC diagnosis after review. Among the 58 remaining pts with confirmed LCNEC, five (8%) had a mixed histology with a NSCLC component. The mean age of the population was 65 years, mainly mens (86%) and former or current heavy smokers (93%). Fifty-five and 51 tumors samples were respectively available for TC and IC PD-L1 IHC expression. PD-L1 expression on TC was found in only 12% of the samples (7/55), while 76% (39/ 51) of the samples shows IC PD-L1 positive, with respectively 18 (35%) IC3, 8 (14%) IC 2, and 13 (25%) IC1. Conclusion: Histological diagnosis of LCNEC remains difficult, and prospective studies concerning patients with LCNEC should include a centrally pathological review of tumors. The PD-L1 expression pattern looks different for LCNEC in comparison to other lung carcinomas, as few TC were found positive although IC were frequently positive, half of the tumors having high PD-L1 IC infiltration (IC3/2). This PD-L1 pattern may suggest a potential effectiveness of therapeutic anti PD-L1 antibodies and this hypothesis have to be addressed in clinical trials. Keywords: large cell neuroendocrine carcinoma, PD-L1 expression, Immune infiltrating cells 
